Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
05 Fevereiro 2024 - 11:00AM
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology
company focused on developing precision therapies for genetically
defined diseases, today announced its upcoming posters for
bezuclastinib at the 2024 American Academy of Allergy Asthma &
Immunology Annual Meeting (AAAAI) being held in Washington, D.C.
from February 23-26, 2024. The company will host a virtual investor
webcast on Friday, February 23 at 8:00 a.m. ET.
Poster Details
Poster Presentation Title: Initial Results
from Summit: An Ongoing, 3-Part, Multi-Center, Randomized,
Double-Blind, Placebo-Controlled Phase 2 Clinical Study of
Bezuclastinib in Adult Patients with NonAdvanced Systemic
Mastocytosis (NonAdvSM)Session Date and
Time: February 25, 2024 – 9:45am – 10:45am
ETSession Title: Mast Cell DisordersPoster
Number: 694Location: Walter E.
Washington Convention Center, Level 2, Hall D; Washington, DC
Poster Presentation Title: Physician and
Patient Perspectives on Relevant and Burdensome Symptoms of
Non-Advanced Systemic MastocytosisSession Date and
Time: February 25, 2024 – 9:45am – 10:45am
ETSession Title: Mast Cell DisordersPoster
Number: 688Location: Walter E.
Washington Convention Center, Level 2, Hall D; Washington, DC
Investor Webcast Information
A webcast on Friday, February 23 at 8:00 a.m. ET to discuss the
SUMMIT Part 1b data will be led by Andrew Robbins, Cogent’s
President and Chief Executive Officer, and will include a
presentation by PD Dr. Frank Siebenhaar, M.D., Head University
Outpatient Clinic, Institute of Allergology, Charité -
Universitätsmedizin Berlin. The event will be accessible on
the Investors and Media page of Cogent’s website
at investors.cogentbio.com/events. A replay will be available
approximately two hours after the completion of the event and will
be archived for up to 30 days.
About Cogent Biosciences, Inc.Cogent
Biosciences is a biotechnology company focused on developing
precision therapies for genetically defined diseases. The most
advanced clinical program, bezuclastinib, is a selective tyrosine
kinase inhibitor that is designed to potently inhibit the KIT D816V
mutation as well as other mutations in KIT exon 17. KIT D816V is
responsible for driving systemic mastocytosis, a serious disease
caused by unchecked proliferation of mast cells. Exon 17 mutations
are also found in patients with advanced gastrointestinal stromal
tumors (GIST), a type of cancer with strong dependence on oncogenic
KIT signaling. In addition to bezuclastinib, the Cogent Research
Team is developing a portfolio of novel targeted therapies to help
patients fighting serious, genetically driven diseases initially
targeting mutations in FGFR2, ErbB2 and
PI3Kα (genes/pathways). Cogent Biosciences is based in
Waltham, MA and Boulder, CO. Visit our website for more information
at www.cogentbio.com. Follow Cogent Biosciences on social
media: X (formerly known as
Twitter) and LinkedIn. Information that
may be important to investors will be routinely posted on our
website and X.
Contact:Christi WaarichSenior Director,
Investor Relationschristi.waarich@cogentbio.com617-830-1653
Cogent Biosciences (NASDAQ:COGT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cogent Biosciences (NASDAQ:COGT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024